ASCO 2017 | Palbociclib: single-agent or in combination for the treatment of breast cancer

Luca Malorni, MD, PhD, from the Hospital of Prato, Instituto Toscano Tumori, Italy, gives us an insight into the TREnd trial (NCT02549430), an ongoing Phase II trial assessing the activity of palbociclib in monotherapy and in combination with endocrine therapy on which patients have progressed in the previous line for advanced breast cancer to reverse endocrine resistance. Due to missing data on single-agent palbociclib, it is difficult to evaluate the clinical activity of the drug in monotherapy, as detailed by Dr. Malorni in this segment. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.